Tags

Type your tag names separated by a space and hit enter

Rhythm-specific pharmacological modulation of subthalamic activity in Parkinson's disease.
Exp Neurol. 2004 Oct; 189(2):369-79.EN

Abstract

The subthalamic nucleus (STN) has a key role in the pathophysiology of Parkinson's disease and is the primary target for high-frequency deep brain stimulation (DBS). The STN rest electrical activity in Parkinson's disease, however, is still unclear. Here we tested the hypothesis that pharmacological modulation of STN activity has rhythm-specific effects in the classical range of EEG frequencies, below 50 Hz. We recorded local field potentials (LFPs) through electrodes implanted in the STN of patients with Parkinson's disease (20 nuclei from 13 patients). After overnight withdrawal of antiparkinsonian therapy, LFPs were recorded at rest both before (off) and after (on) acute administration of different antiparkinsonian drugs: levodopa, apomorphine, or orphenadrine. In the off-state, STN LFPs showed clearly defined peaks of oscillatory activity below 50 Hz: at low frequencies (2-7 Hz), in the alpha (7-13 Hz), low-beta (13-20 Hz), and high-beta range (20-30 Hz). In the on-state after levodopa and apomorphine administration, low-beta activity significantly decreased and low-frequency activity increased. In contrast, orphenadrine increased beta activity. Power changes elicited by levodopa and apomorphine at low frequencies and in the beta range were not correlated, whereas changes in the alpha band, which were globally not significant, correlated with the beta rhythm (namely, low beta: 13-20 Hz). In conclusion, in the human STN, there are at least two rhythms below 50 Hz that are separately modulated by antiparkinsonian medication: one at low frequencies and one in the beta range. Multiple rhythms are consistent with the hypothesis of multiple oscillating systems, each possibly correlating with specific aspects of human STN function and dysfunction.

Authors+Show Affiliations

Department of Neurological Sciences, IRCCS Ospedale Maggiore di Milano, Università di Milano, 20122 Milan, Italy. alberto.priori@unimi.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

15380487

Citation

Priori, A, et al. "Rhythm-specific Pharmacological Modulation of Subthalamic Activity in Parkinson's Disease." Experimental Neurology, vol. 189, no. 2, 2004, pp. 369-79.
Priori A, Foffani G, Pesenti A, et al. Rhythm-specific pharmacological modulation of subthalamic activity in Parkinson's disease. Exp Neurol. 2004;189(2):369-79.
Priori, A., Foffani, G., Pesenti, A., Tamma, F., Bianchi, A. M., Pellegrini, M., Locatelli, M., Moxon, K. A., & Villani, R. M. (2004). Rhythm-specific pharmacological modulation of subthalamic activity in Parkinson's disease. Experimental Neurology, 189(2), 369-79.
Priori A, et al. Rhythm-specific Pharmacological Modulation of Subthalamic Activity in Parkinson's Disease. Exp Neurol. 2004;189(2):369-79. PubMed PMID: 15380487.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rhythm-specific pharmacological modulation of subthalamic activity in Parkinson's disease. AU - Priori,A, AU - Foffani,G, AU - Pesenti,A, AU - Tamma,F, AU - Bianchi,A M, AU - Pellegrini,M, AU - Locatelli,M, AU - Moxon,K A, AU - Villani,R M, PY - 2004/03/09/received PY - 2004/05/26/revised PY - 2004/06/02/accepted PY - 2004/9/24/pubmed PY - 2004/10/29/medline PY - 2004/9/24/entrez SP - 369 EP - 79 JF - Experimental neurology JO - Exp Neurol VL - 189 IS - 2 N2 - The subthalamic nucleus (STN) has a key role in the pathophysiology of Parkinson's disease and is the primary target for high-frequency deep brain stimulation (DBS). The STN rest electrical activity in Parkinson's disease, however, is still unclear. Here we tested the hypothesis that pharmacological modulation of STN activity has rhythm-specific effects in the classical range of EEG frequencies, below 50 Hz. We recorded local field potentials (LFPs) through electrodes implanted in the STN of patients with Parkinson's disease (20 nuclei from 13 patients). After overnight withdrawal of antiparkinsonian therapy, LFPs were recorded at rest both before (off) and after (on) acute administration of different antiparkinsonian drugs: levodopa, apomorphine, or orphenadrine. In the off-state, STN LFPs showed clearly defined peaks of oscillatory activity below 50 Hz: at low frequencies (2-7 Hz), in the alpha (7-13 Hz), low-beta (13-20 Hz), and high-beta range (20-30 Hz). In the on-state after levodopa and apomorphine administration, low-beta activity significantly decreased and low-frequency activity increased. In contrast, orphenadrine increased beta activity. Power changes elicited by levodopa and apomorphine at low frequencies and in the beta range were not correlated, whereas changes in the alpha band, which were globally not significant, correlated with the beta rhythm (namely, low beta: 13-20 Hz). In conclusion, in the human STN, there are at least two rhythms below 50 Hz that are separately modulated by antiparkinsonian medication: one at low frequencies and one in the beta range. Multiple rhythms are consistent with the hypothesis of multiple oscillating systems, each possibly correlating with specific aspects of human STN function and dysfunction. SN - 0014-4886 UR - https://www.unboundmedicine.com/medline/citation/15380487/Rhythm_specific_pharmacological_modulation_of_subthalamic_activity_in_Parkinson's_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014488604002298 DB - PRIME DP - Unbound Medicine ER -